Forward-looking industries have begun exploring the advantages of ablation devices, leading to a steady market. Growth opportunities are emerging, and BCC Research’s latest report helps players identify opportunities for ablation devices across various product categories and geographical segments.
Radiofrequency ablation (RFA) uses heat to destroy tissue. It is used to treat chronic pain caused by conditions including arthritis of the spine and join pain, cancer pain, facial pain caused by trigeminal neuralgia, peripheral nerve pain, tumors to kill cells, and the treatment of primary and secondary liver cancer. The challenge with liver cancer is that it cannot be diagnosed until the patient presents severe symptoms; however, by then, the tumor has usually grown too big to treat with normal surgery. RFA allows treatment of such late-diagnosed liver cancer. This technological innovation of radio frequency can treat inoperable tumors. In recent years, RF ablation balloons have also been developed.
Pulsed-field ablation (PFA) has recently emerged as an emerging technology for ablation. It is a new adaptation of low-energy DC catheter ablation. It uses large electrodes to reduce current density. PFA is a tool for non-thermal ablation. Based on recent studies, the myocardium is more susceptible to PFA’s effects than other tissues, particularly the esophagus and nerves. Therefore, PFA is less likely to produce collateral damage than RF ablation during pulmonary vein isolation procedures.
Robotic tissue ablation is a clinical procedure the employs robots to remove or destroy the diseased tissue or tumor from the body. This system has a robotic surgical arm that helps in removing diseased tissue. This technique prevents conventional manual ablation methods. Its superiority, driven by increased precision, stability and efficacy, assures safety from potential human errors. Robotic tissue ablation procedures provide exceptional accuracy, quick healing and excellent outcomes, making them a significant innovation in medicine. In the near future, the surgery market is expected to be driven by robotic tissue ablation, which will surpass traditional ablation surgery methods.
Endometrial ablation is another segment where innovations are likely to change how gynecological ailments can be treated. New devices will be launched, and strategic partnerships will be formed for innovations in endometrial ablation. Microwave endometrial ablation is a new treatment for dysfunctional uterine bleeding that involves applying microwave energy to the endometrium. Other innovations emerging in the ablation devices market include cardiac ablation, electrophysiology mapping and cancer ablation devices.
Nanomaterials in cryoablation are a new opportunity. Despite its ease of use and efficiency, cryoablation still faces problems such as inadequate ice formation, the possibility of the ice ball overextending into healthy tissues and low tumor cell death. Due to these factors, recurrence can occur in tumors treated with cryoablation. Image-guided cryoablation is needed for the precision targeting of tumors. Nanomaterials can act as both imaging contrast agents and vehicles of chemotherapeutic drugs. Nanoparticles can increase and direct ice growth, protect healthy tissues from cryoinjury, damage cells via modulating their membranes, locally release drugs and enhance imaging.
Alternatively, consider becoming a member of the BCC Research library, and gain access to the full catalog of reports within the healthcare category. Enquire today to find out more.
We are your trusted research partner, providing actionable insights and custom consulting across life sciences, advanced materials, and technology. Allow BCC Research to nurture your smartest business decisions today, tomorrow, and beyond.Contact Us